Equine

Equisul-SDT® (sulfadiazine/trimethoprim)

Equisul-SDT® is a broad-spectrum, FDA-approved oral suspension formulated specifically for horses. It is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of Streptococcus equi subsp. zooepidemicus. This fast-acting combination of sulfadiazine and trimethoprim delivers targeted antibacterial action, helping clear infection and support respiratory recovery.

Equisul-SDT® offers a cleaner, simpler alternative to crushing tablets - designed to maintain therapeutic blood levels through twice-daily dosing for equine respiratory care in both clinical and field settings.

Package Presentation

135 mL
Reorder No. 28000
280 mL
with draw off cap
Reorder No. 28003
560 mL
with draw off cap
Reorder No. 28002
900 mL
Reorder No. 28001

Key Features

  • Safety was demonstrated in a controlled study in horses at 1X, 3X and 5X the recommended dose for 30 days1
  • Low incidence of side effects in controlled safety studies1
  • Convenient, apple-flavored liquid formulation containing sulfadiazine 333 mg/mL and trimethoprim 67 mg/mL
  • Approved by FDA under NADA 141-360
  • Manufactured under GMP standards for quality and consistency

Safety Information

Do not use Equisul-SDT® in horses intended for human consumption. Equisul-SDT® is contraindicated in horses with a known allergy to sulfadiazine, sulfonamide class antimicrobials, or trimethoprim. Not for use in humans. For use in animals only. Keep this and all drugs out of the reach of children. Avoid direct contact of the product with the skin, eyes, mouth, and clothing. Persons with a known sensitivity to sulfonamides or trimethoprim should avoid exposure to this product. Consult a physician in the case of accidental human exposure. Adverse events observed in animals included loose stool, colic, and diarrhea. For complete safety information, refer to the package insert.

1Based on FOI summaries and label claims.